Canada's Research-Based Pharmaceutical Companies (Rx&D)

Canada's Research-Based Pharmaceutical Companies (Rx&D)

November 05, 2014 15:56 ET

Research into innovative medicines gives Canadian man the opportunity to live

OTTAWA, ONTARIO--(Marketwired - Nov. 5, 2014) -

Editors Note: There are a photo and a video associated with this Press Release.

Gérard Genest was born with hemophilia, a rare disorder in which a person's blood does not clot normally. He received several blood transfusions over the course of his life. As a child, he was still able to play hockey enjoy time with friends and family.

"When I was a kid, it was pretty hard. I wanted to play with my friends… I played hockey and, believe it or not, I was a goalie… But I was always in the hospital," Says Gérard of his childhood years.

Gérard continued to be active into his adult years. But at 32 years old, when he was told he had contracted Hepatitis C from a blood transfusion, his life changed forever. There were no treatments for him at that time. Over the 25 year that would follow, his liver developed chronic hepatitis which led to cirrhosis and then to liver cancer. A liver transplant was becoming necessary.

Doctors worked hard to keep him alive long enough to try a new medicine they had heard of that could possibly help. He was offered the medicine through a compassionate care program. Compassionate care or patient assistance programs provide patients with information, support and access to innovative medicines.

The treatment lasted 24 weeks but, after only two weeks, the Hepatitis C was undetectable. By the end of the treatment, Gérard was cured of Hepatitis C.

"I was cured; I couldn't believe it! I am so grateful to everyone who worked on the research and or getting me to the treatment. They gave me the opportunity to live," Added Gérard.

Now, Gérard is getting healthier every day and looks forward to spending quality time with his family and friends, doing the activities he's always loved: biking, swimming, skiing, and skating.

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada's knowledge-based economy, contributing over $3 billion to the Canadian economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.

To view the photo associated with this press release, please visit the following link:

To view the video associated with this press release, please visit the following link:

Contact Information